{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:56:59Z","timestamp":1792411019539,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"FWO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011851","name":"Kom op tegen kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jconrel.2024.04.052","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T17:12:30Z","timestamp":1714842750000},"page":"379-391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria"],"prefix":"10.1016","volume":"370","author":[{"given":"Sofie","family":"Meulewaeter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilke","family":"Aernout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke","family":"Deprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanou","family":"Engelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margo","family":"De Velder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Breckpot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Van Calenbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Asselman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Impens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefaan C.","family":"De Smedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rein","family":"Verbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ine","family":"Lentacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.04.052_bb0005","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0010","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0015","author":"Moderna"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0020","author":"Moderna"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0025","author":"BioNTech"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/14760584.2022.2011226","article-title":"Will the mRNA vaccine platform be the panacea for the development of vaccines against antimicrobial resistant (AMR) pathogens?","volume":"21","author":"Chen","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168385","article-title":"Considerations on the design of lipid-based mRNA vaccines against cancer","volume":"436","author":"Meulewaeter","year":"2024","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0040","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0045","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0050","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.983000","article-title":"Palaga, mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model","volume":"13","author":"Sittplangkoon","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn3464","article-title":"Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice","volume":"15","author":"Ramos da Silva","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0065","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jconrel.2021.12.008","article-title":"The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency","volume":"342","author":"Anderluzzi","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001643","article-title":"Adverse effects following anti-COVID-19 vaccination with mRNA-based BNT162b2 are alleviated by altering the route of administration and correlate with baseline enrichment of T and NK cell genes","volume":"20","author":"Syenina","year":"2022","journal-title":"PLoS Biol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0075","article-title":"Reactogenicity and immunogenicity of the intradermal administration of BNT162b2 mRNA vaccine in healthy adults who were primed with an inactivated SARS-CoV-2 vaccine","volume":"X, 12","author":"Temtanakitpaisan","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0080","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0085","first-page":"1655","article-title":"Broadening the message: a nanovaccine co-loaded with messenger RNA and alpha-GalCer induces antitumor immunity through conventional and natural killer T cells","volume":"13","author":"Verbeke","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0090","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1084\/jem.189.7.1121","article-title":"The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells","volume":"189","author":"Kitamura","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0095","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1084\/jem.188.8.1521","article-title":"CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution","volume":"188","author":"Brossay","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nri3369","article-title":"Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions","volume":"13","author":"Brennan","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21113909","article-title":"License to kill: when iNKT cells are granted the use of lethal cytotoxicity","volume":"21","author":"Diaz-Basabe","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0110","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.4049\/jimmunol.0802430","article-title":"Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine","volume":"182","author":"Ko","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0115","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2014.995562","article-title":"Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice","volume":"4","author":"Gebremeskel","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0120","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1172\/JCI36264","article-title":"Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans","volume":"118","author":"De Santo","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0130","volume":"WO2017070618A1","author":"Valiante","year":"2017","journal-title":"Cancer Vacc."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0135","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4049\/jimmunol.180.1.309","article-title":"Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals","volume":"180","author":"Kreiter","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0145","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.4049\/jimmunol.172.11.6649","article-title":"Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules","volume":"172","author":"Bonehill","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2023.03.039","article-title":"Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures","volume":"357","author":"Meulewaeter","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0155","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrmicro1413","article-title":"Listeria monocytogenes: a multifaceted model","volume":"4","author":"Hamon","year":"2006","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0160","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.micinf.2007.05.008","article-title":"Innate and adaptive immune responses to Listeria monocytogenes: a short overview","volume":"9","author":"Zenewicz","year":"2007","journal-title":"Microbes Infect."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0165","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nri1461","article-title":"Immune responses to Listeria monocytogenes","volume":"4","author":"Pamer","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33721-y","article-title":"Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes","volume":"13","author":"Mayer","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202312026","article-title":"Physicochemical targeting of lipid nanoparticles to the lungs induces clotting: mechanisms and solutions","author":"Omo-Lamai","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0180","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0185","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1073\/pnas.0408288102","article-title":"Glycolipid presentation to natural killer T cells differs in an organ-dependent fashion","volume":"102","author":"Schmieg","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0190","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.clim.2010.04.019","article-title":"Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide","volume":"136","author":"Bontkes","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0195","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/eji.201041359","article-title":"Intranasal but not intravenous delivery of the adjuvant alpha-galactosylceramide permits repeated stimulation of natural killer T cells in the lung","volume":"41","author":"Courtney","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0200","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.76586","article-title":"Longitudinal analysis of invariant natural killer T cell activation reveals a cMAF-associated transcriptional state of NKT10 cells","volume":"11","author":"Kane","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0205","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1172\/JCI72308","article-title":"IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset","volume":"124","author":"Sag","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0210","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.7150\/thno.85106","article-title":"Nanobody-mediated SPECT\/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8(+) T cell and iNKT cell activating mRNA vaccine","volume":"13","author":"Ertveldt","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.04.052_bb0215","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fimmu.2015.00226","article-title":"The response of CD1d-restricted invariant NKT cells to microbial pathogens and their products","volume":"6","author":"Van Kaer","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0220","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1128\/IAI.01441-09","article-title":"Alpha-galactosylceramide promotes killing of Listeria monocytogenes within the macrophage phagosome through invariant NKT-cell activation","volume":"78","author":"Emoto","year":"2010","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0225","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4049\/jimmunol.175.2.1137","article-title":"Invariant V alpha 14+ NKT cells participate in the early response to enteric Listeria monocytogenes infection","volume":"175","author":"Ranson","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0230","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.4049\/jimmunol.0900858","article-title":"Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin","volume":"183","author":"Venkataswamy","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0235","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41590-023-01562-6","article-title":"mRNA vaccine against malaria tailored for liver-resident memory T cells","volume":"24","author":"Ganley","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0240","article-title":"Unsaturated, trialkyl ionizable lipids are versatile lipid-nanoparticle components for therapeutic and vaccine applications","volume":"35","author":"Lam","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2024.04.052_bb0245","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11095-004-1873-z","article-title":"A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA","volume":"22","author":"Jeffs","year":"2005","journal-title":"Pharm. Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924002815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924002815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T08:09:18Z","timestamp":1740211758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924002815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":49,"alternative-id":["S0168365924002815"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.04.052","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.04.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}